Flash glucose monitoring helps achieve better glycemic control than conventional self-monitoring of blood glucose in non-insulin-treated type 2 diabetes: a randomized controlled trial.


Journal

BMJ open diabetes research & care
ISSN: 2052-4897
Titre abrégé: BMJ Open Diabetes Res Care
Pays: England
ID NLM: 101641391

Informations de publication

Date de publication:
06 2020
Historique:
received: 12 12 2019
revised: 05 05 2020
accepted: 13 05 2020
entrez: 11 6 2020
pubmed: 11 6 2020
medline: 22 6 2021
Statut: ppublish

Résumé

The present study aimed to evaluate the effects of flash glucose monitoring (FGM) and conventional self-monitoring of blood glucose (SMBG) on glycemic control in patients with non-insulin-treated type 2 diabetes. In this 24-week, multicenter, open-label, randomized (1:1), parallel-group study, patients with non-insulin-treated type 2 diabetes at five hospitals in Japan were randomly assigned to the FGM (n=49) or SMBG (n=51) groups and were provided each device for 12 weeks. The primary outcome was change in glycated hemoglobin (HbA1c) level, and was compared using analysis of covariance model that included baseline values and group as covariates. Forty-eight participants in the FGM group and 45 in the SMBG group completed the study. The mean HbA1c levels were 7.83% (62.1 mmol/mol) in the FGM group and 7.84% (62.2 mmol/mol) in the SMBG group at baseline, and the values were reduced in both FGM (-0.43% (-4.7 mmol/mol), p<0.001) and SMBG groups (-0.30% (-3.3 mmol/mol), p=0.001) at 12 weeks. On the other hand, HbA1c was significantly decreased from baseline values in the FGM group, but not in the SMBG group at 24 weeks (FGM: -0.46% (-5.0 mmol/mol), p<0.001; SMBG: -0.17% (-1.8 mmol/mol), p=0.124); a significant between-group difference was also observed (difference -0.29% (-3.2 mmol/mol), p=0.022). Diabetes Treatment Satisfaction Questionnaire score was significantly improved, and the mean glucose levels, SD of glucose, mean amplitude of glycemic excursions and time in hyperglycemia were significantly decreased in the FGM group compared with the SMBG group. Glycemic control was better with FGM than with SMBG after cessation of glucose monitoring in patients with non-insulin-treated type 2 diabetes. UMIN000026452, jRCTs041180082.

Identifiants

pubmed: 32518063
pii: 8/1/e001115
doi: 10.1136/bmjdrc-2019-001115
pmc: PMC7292039
pii:
doi:

Substances chimiques

Blood Glucose 0
Hypoglycemic Agents 0
Glucose IY9XDZ35W2

Banques de données

UMIN-CTR
['UMIN000026452']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: HA reports grants and speaker honoraria from Abbott Japan outside the submitted work.

Références

Diabetes Care. 2019 Jan;42(Suppl 1):S61-S70
pubmed: 30559232
Lancet. 2016 Nov 5;388(10057):2254-2263
pubmed: 27634581
Clin Med Insights Endocrinol Diabetes. 2019 Jul 01;12:1179551419861102
pubmed: 31308786
Diabetes Care. 2013 Jul;36(7):2009-14
pubmed: 23378621
Exp Clin Endocrinol Diabetes. 2006 Jul;114(7):384-8
pubmed: 16915542
Am J Med. 2005 Apr;118(4):422-5
pubmed: 15808142
Diabetes Technol Ther. 2005 Apr;7(2):253-63
pubmed: 15857227
Diab Vasc Dis Res. 2019 Jul;16(4):385-395
pubmed: 31271312
Diabetes Technol Ther. 2013 Aug;15(8):662-9
pubmed: 23844570
Diabetes Care. 2019 Jul;42(7):1178-1184
pubmed: 31036546
Diabetes Metab. 2003 Dec;29(6):587-94
pubmed: 14707887
Diabetes Technol Ther. 2005 Dec;7(6):849-62
pubmed: 16386091
Am J Med. 2001 Jul;111(1):1-9
pubmed: 11448654
Diabetol Int. 2018 Mar 27;9(1):1-45
pubmed: 30603347
Am J Manag Care. 2008 Jul;14(7):468-75
pubmed: 18611098
Diabet Med. 1994 Jun;11(5):510-6
pubmed: 8088133
Endocrinol Diabetes Metab. 2018 Jun 17;1(3):e00023
pubmed: 30815557
Int J Environ Res Public Health. 2018 May 09;15(5):
pubmed: 29747423
J Diabetes Sci Technol. 2017 Mar;11(2):442-443
pubmed: 27464754
Diabetes Ther. 2017 Feb;8(1):55-73
pubmed: 28000140
Exp Clin Endocrinol Diabetes. 2019 Jun 11;:
pubmed: 31185506
Diabetologia. 2019 Aug;62(8):1349-1356
pubmed: 31177314
Open Med. 2010;4(2):e102-13
pubmed: 21686299
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088
Diabetes Technol Ther. 2009 Jun;11 Suppl 1:S45-54
pubmed: 19469677
J Med Internet Res. 2016 Apr 19;18(4):e86
pubmed: 27095386

Auteurs

Eri Wada (E)

Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Takeshi Onoue (T)

Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan t-onoue@med.nagoya-u.ac.jp arima105@med.nagoya-u.ac.jp.

Tomoko Kobayashi (T)

Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Tomoko Handa (T)

Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Ayaka Hayase (A)

Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Masaaki Ito (M)

Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Mariko Furukawa (M)

Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Takayuki Okuji (T)

Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Norio Okada (N)

Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Shintaro Iwama (S)

Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Mariko Sugiyama (M)

Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Taku Tsunekawa (T)

Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Hiroshi Takagi (H)

Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Daisuke Hagiwara (D)

Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Yoshihiro Ito (Y)

Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Department of CKD Initiatives Internal Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Hidetaka Suga (H)

Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Ryoichi Banno (R)

Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Research Center of Health, Physical Fitness and Sports, Nagoya University, Nagoya, Japan.

Yachiyo Kuwatsuka (Y)

Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.

Masahiko Ando (M)

Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.

Motomitsu Goto (M)

Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Hiroshi Arima (H)

Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan t-onoue@med.nagoya-u.ac.jp arima105@med.nagoya-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH